These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 2185538)

  • 1. Dopaminergic mechanisms in idiopathic and drug-induced psychoses.
    Lieberman JA; Kinon BJ; Loebel AD
    Schizophr Bull; 1990; 16(1):97-110. PubMed ID: 2185538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulant-induced psychosis, the dopamine theory of schizophrenia, and the habenula.
    Ellison G
    Brain Res Brain Res Rev; 1994 May; 19(2):223-39. PubMed ID: 7914793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical aspects and follow-up of dopamine-induced psychoses in continuous dopaminergic therapy and their implications for the dopamine hypothesis of schizophrenic symptoms].
    Heinz A; Przuntek H; Winterer G; Pietzcker A
    Nervenarzt; 1995 Sep; 66(9):662-9. PubMed ID: 7477603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization.
    Yui K; Goto K; Ikemoto S; Ishiguro T; Angrist B; Duncan GE; Sheitman BB; Lieberman JA; Bracha SH; Ali SF
    Mol Psychiatry; 1999 Nov; 4(6):512-23. PubMed ID: 10578232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.
    Batki SL; Harris DS
    Am J Addict; 2004; 13(5):461-70. PubMed ID: 15764424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of compulsivity of drug abuse on dopaminergic modulation of attentional bias in stimulant dependence.
    Ersche KD; Bullmore ET; Craig KJ; Shabbir SS; Abbott S; Müller U; Ooi C; Suckling J; Barnes A; Sahakian BJ; Merlo-Pich EV; Robbins TW
    Arch Gen Psychiatry; 2010 Jun; 67(6):632-44. PubMed ID: 20530013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphetamine psychosis and schizophrenia: a dual model.
    Kokkinidis L; Anisman H
    Neurosci Biobehav Rev; 1981; 5(4):449-61. PubMed ID: 7033842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study.
    Rosse RB; Collins JP; Fay-McCarthy M; Alim TN; Wyatt RJ; Deutsch SI
    Clin Neuropharmacol; 1994 Aug; 17(4):359-69. PubMed ID: 9316684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous amphetamine intoxication: an animal model of the acute psychotic episode.
    Ellison GD; Eison MS
    Psychol Med; 1983 Nov; 13(4):751-61. PubMed ID: 6320247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditioned dopaminergic activity.
    Schiff SR
    Biol Psychiatry; 1982 Feb; 17(2):135-54. PubMed ID: 7200377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of dopamine in the mouse frontal cortex: a new hypothesis of behavioral sensitization to amphetamine and cocaine.
    Karler R; Calder LD; Thai DK; Bedingfield JB
    Pharmacol Biochem Behav; 1998 Dec; 61(4):435-43. PubMed ID: 9802839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphetamine injection into the ventral mesencephalon sensitizes rats to peripheral amphetamine and cocaine.
    Kalivas PW; Weber B
    J Pharmacol Exp Ther; 1988 Jun; 245(3):1095-102. PubMed ID: 3385638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central stimulant abuse: neurochemistry and pharmacotherapy.
    Dackis CA; Gold MS; Pottash AL
    Adv Alcohol Subst Abuse; 1986; 6(2):7-21. PubMed ID: 2886014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neural mechanisms of the reinforcing action of cocaine.
    Wise RA
    NIDA Res Monogr; 1984; 50():15-33. PubMed ID: 6440023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects.
    Angrist B; Gershon S
    Adv Biochem Psychopharmacol; 1977; 16():677-80. PubMed ID: 883566
    [No Abstract]   [Full Text] [Related]  

  • 17. Biological effects of central nervous system stimulants.
    Holman RB
    Addiction; 1994 Nov; 89(11):1435-41. PubMed ID: 7841853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological treatment of substance-abusing schizophrenic patients.
    Siris SG
    Schizophr Bull; 1990; 16(1):111-22. PubMed ID: 1970669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
    Javitt DC
    Hillside J Clin Psychiatry; 1987; 9(1):12-35. PubMed ID: 2820854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic sensitivity and cocaine abuse: response to apomorphine.
    Hollander E; Nunes E; DeCaria CM; Quitkin FM; Cooper T; Wager S; Klein DF
    Psychiatry Res; 1990 Aug; 33(2):161-9. PubMed ID: 2243893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.